论文部分内容阅读
为了观察吉非替尼治疗老年非小细胞肺癌(non-small celllung cancer,NSCLC)的有效性和毒副反应,回顾性研究32例经病理学或细胞学确诊的老年NSCLC,应用吉非替尼(250mg,口服1次/d)治疗,直到病情进展或出现严重不良反应。32例患者,PR8例(25.0%),SD17例(53.1%),PD7例(21.9%),有效率(CR+PR)为25%,疾病控制率(CR+PR+SD)为78.1%。女性有效率优于男性,P=0.013。病理、分期及吸烟史等各亚组之间疗效对比均差异无统计学意义,P>0.05。中位生存时间(MST)10.1个月,中位疾病进展时间(MTTP)5.7个月。腺癌和肺泡癌患者的中位生存时间及中位疾病进展时间优于鳞癌及大细胞癌患者,P值分别为0.037和0.024。吉非替尼最主要的毒副反应是皮疹(62.5%)、腹泻(30%)、皮肤干燥(46.9%)及食欲减退(25%)。3例因严重皮疹和腹泻而中断治疗。初步研究结果提示,吉非替尼单药治疗老年NSCLC疗效肯定,毒副反应相对较小,患者耐受性好。
In order to observe the efficacy and toxicity of gefitinib in the treatment of elderly non-small cell lung cancer (NSCLC), 32 NSCLC patients with pathologically confirmed or cytologically confirmed NSCLC were retrospectively studied. (250mg, oral 1 / d) treatment until the progression of the disease or serious adverse reactions. 32 patients had PR8 (25.0%), SD17 (53.1%), PD7 (21.9%), effective rate (CR + PR) was 25% and disease control rate (CR + PR + SD) was 78.1%. Women were more effective than men, P = 0.013. Pathological, staging and smoking history and other sub-groups were no significant difference in the efficacy of comparison, P> 0.05. The median survival time (MST) was 10.1 months and the median time to disease progression (MTTP) was 5.7 months. The median survival time and median disease progression time in patients with adenocarcinoma and alveolar carcinoma were superior to those with squamous cell carcinoma and large cell carcinoma, with P values of 0.037 and 0.024, respectively. The most common side effects of gefitinib were rash (62.5%), diarrhea (30%), dry skin (46.9%) and loss of appetite (25%). Three patients discontinued treatment due to severe rash and diarrhea. Preliminary results suggest that gefitinib monotherapy for the treatment of elderly NSCLC positive effect, the toxicity is relatively small, patients with good tolerance.